Conclusion: Even though management goal is directed at remission induction in the earliest stages of rheumatoid arthritis with molecular targeted therapies is mostly in the developed countries, in rural parts of the developing countries low rate of adherence to follow-up appointments and medications is still an important difficulty in management. Patients receiving biologic DMARDs have higher adherence to treatment. Awareness and education of patients in rheumatoid arthritis, as well as in all chronic diseases, is most important aspect of management.

Disclosure of Interests: None declared

AB0351 ELDERLY-ONSET RHEUMATOID ARTHRITIS (EORA): DIFFERENCES ACCORDING TO CLINICAL DEBUT AND SEROLOGICAL POSITIVITY

Maria Andreina Terán Tinedo, Cristina Piróan Moratalla, Jose Renato Quiñones Torres. Hospital Universitario Ramon y Cajal, Madrid, Spain

Background: In patients with Elderly-onset Rheumatoid Arthritis (EORA), it has been described a clinical debut mimicking polyarthritis rheumatica with rhizomelic pseudopolyarthritis, in contrast with the clinical profile of patients with Rheumatoid Arthritis similar to younger patients. We compare in our study these two profiles of the disease.

Objectives: To describe and compare the differences according to clinical debut, serological positivity and its implications in terms of treatment and prognostic factors in patients with Elderly-onset Rheumatoid Arthritis (EORA).

Methods: Patients with a diagnosis of RA over 65 years of age according to ACR/EULAR 2010 criteria were included. A database was created with rhizomelic pseudopolyarthritis, the positivity of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPs), elevation of acute phase reactants (APR), the presence of erosions and the treatment required. Finally, data was analyzed according to clinical debut, serological positivity and prognostic factors.

Results: 83 patients diagnosed of EORA were included, with an average age of 73.8 years. 71.2% had positive RF (58.75% high titers) and 62.5% had positive ACP (52.3% high titer). 24/83 patients (29%) debuted with a polyarthritis-like symptoms (rhizomelic pseudopolyarthritis), the positivity of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPs), elevation of acute phase reactants (APR), the presence of erosions and the treatment required. Regarding treatment, 15% were treated only with corticosteroids, 65% required treatment with DMARDs and 15% were receiving biological treatment. 42/83 patients (50%) had erosions on plain X-rays. Of those patients with a polyarthritis-like profile, 52.2% (43/83) had positive RF but most of them had low titers (61%). On the other hand, patients without polyarthritis-like symptoms had positive RF in 78% of the cases and most of them at high titers (66%, p = 0.01). In the first group there was less positivity for ACP (28%, p = 0.00004) and half of them had low titers. Erosions were observed in only 30% of the patients with polyarthritis-like symptoms, while those without this profile had more erosions (58%, p = 0.02) and higher APR (50%, p = 0.026). Regarding treatment, in the group with polyarthritis-like symptoms only 34% were treated with corticosteroids, 65% required DMARDs and no patients had received biological treatment, whereas in the non-polyarthritis group, 88% required DMARDs and 21% required biologics (p = 0.01 for both results). Analyzing patients with positive RF and ACPs at high titer, 93% received treatment with DMARDs and 24% required biological treatment. 65% had persistent elevation of APR and 48% presented erosions on plain X-rays. Only 2 patients with positive RF and ACPs at high titer debuted with a polyarthritis-like symptoms.

Conclusion: Patients with EORA with polyarthritis-like symptoms tend to have less erosions and a higher prevalence of negative RF and ACP or at low titers. These patients usually require less DMARDs and biological treatments to control the disease unlike patients with non-polyarthritis symptoms. On the other hand, patients with high RF and ACPA titers have more erosions and elevated APR during follow-up but do not usually experience polyarthritis-like symptoms.

REFERENCE

Acknowledgement: None
Disclosure of Interests: None declared

AB0352 HIGH PREVALENCE OF ANTICIPATORY AND ASSOCIATIVE SYMPTOMS OF METHOTREXATE INTOLERANCE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Rawohe Tekaya, Wafa Triji, Aicha Ben Tekaya, Olfa Saidane, Ines Mahmoud, Leila Abdelmoula, R.Tekaya, W. Triki, A. Ben Tekaya, Oo.Saidane, I.Mahmoud, L. Abdelmoula. Charles Nicolle Hospital, Rheumatology, Tunis, Tunisia

Background: Methotrexate (MTX) is the most widely used anti-rheumatic drug in the treatment of Rheumatoid Arthritis (RA) due to low costs, efficacy and an acceptable safety profile. However MTX has certain side effects. The most common side effects include the gastrointestinal tract not only after taking MTX, but also before MTX intake (anticipatory) and when thinking of MTX (associative).

Objectives: The aim of this study was to assess the prevalence of MTX intolerance particularly the anticipatory and associative symptoms using the validated methotrexate intolerance Severity Score (MISS) (1).

Methods: We performed a cross-sectional descriptive study that involved patients with RA and treated by MTX for more than 3 months, compiled from Charles Nicolle hospital’s rheumatologic department. The tolerance of MTX was assessed by the MISS questionnaire. The MISS Questionnaire includes five elements: abdominal pain, nausea, vomiting, fatigue, and behavioral symptoms of restlessness, crying, irritability and drug refusal. Each element is evaluated after intake of MTX. MTX intolerance was defined as ≥6 points on the MISS, with at least 1 point on anticipatory, associative or behavioral adverse effects.

Results: A total of 100 RA patients (87 women and 13 men) with a mean age of 53.5 years. The MTX was administered by oral route in 91% of patients; the other 9% received it by intramuscular way. The average MTX weekly dose was 15,4mg. The average MTX duration was 76.7 months. All patients received folic acid with an average of 7.6 mg a week. MTX intolerance was found in 36% of patients. Abdominal pain was the most common symptom occurring in 55% of patients and up to 91.66% in MTX-intolerant patients, followed by nausea in 51% of patients and in 86.11% of MTX-intolerant patients vomiting in 16% of patients and in 44.44% of MTX intolerant-patients. Anticipatory and associative abdominal pain affected 72.2% and 69.4 of intolerant-patients respectively. Anticipatory and associative nausea were found in 58,3% and 59% of intolerant-patients respectively. Anticipatory vomiting occurred in 16.6% of intolerant-patients. Overall, behavioral symptoms occurred in 75% of intolerant-patients, of whom 19.4% refused MTX. Older age was significantly correlated with better tolerance to MTX (p=0,02). There was no correlation between the dose of MTX, the duration of MTX intake and the route of MTX and the MISS score (respectively p=0,7, p=0,07and p=0,2). Also, the use of other disease modifying drugs didn’t worsen the tolerance of MTX.

Conclusion: To conclude intolerance to MTX is frequently seen in RA. In addition to gastrointestinal symptoms after taking MTX, RA patients can suffer from anticipatory (MTX-associate gastrointestinal symptoms. We should screen these symptoms earlier using MISS questionnaire in order to improve MTX compliance.

REFERENCE

Acknowledgement: None
Disclosure of Interests: None declared

AB0353 WORSE OFFICE AND 24-HOUR BRACHIAL AND CENTRAL AORTIC BLOOD PRESSURE MONITORING PROFILE IN PATIENTS WITH RHEUMATOID ARTHRITIS COMPARED TO CONTROLS

Elena Troitskaya¹, Sergey Velmakin¹, Svetlana Villevalde², Zhanna Kobalava².
¹Peoples’ Friendship University of Russia (RUDN University), Internal diseases, Moscow, Russian Federation; ²Almagov National Medical Research Centre, St. Petersburg, Russian Federation; ³Peoples’ Friendship University of Russia (RUDN University), Moscow, Russian Federation

Background: Hypertension (HTN) contributes to increased cardio-vascular (CV) morbidity and mortality in RA. Recent European guidelines on the management of HTN encourage wider use of ambulatory blood pressure

Disclosure of Interests: None declared
CAN CANCER TRIGGER AUTOIMMUNITY DISEASE?

Background: Association between cancer and autoimmune diseases are reconsidered by frequent use of immune checkpoint inhibitor and its adverse effects. In addition, the childhood cancer patients have the higher possibility of developing autoimmune disease than general population. The previous research through this may be related to cancer therapy. Furthermore the development of scleroderma in cancer patients harboring the rPOLAR3A cancer mutation suggests that cancer may directly induce autoimmune disease.

Objectives: We examine the features of autoimmune diseases in the patient with pre-existing cancer.

Methods: Date on clinical characteristics, laboratory features, and treatment response from patients with autoimmune disease in our hospital were analyzed retrospectively. We excluded patients who had diagnosed cancer more than 5 years ago, who use immune check point inhibitor, whose symptom became clear by the drug toxicities and endocrine disease, and who had no symptoms but only test abnormalities.

Results: 149 patients consulted our department and 111 patients were included; their median duration of follow-up was 39 months. The median period of diagnosing cancer from autoimmune disease was 17 months, and median age of the patients with autoimmune diseases at diagnosis was 68 years. Baseline manifestations included rheumatoid arthritis (RA) 42%, polymyalgia rheumatica (PMR) 20%, systemic scleroderma (SSc) 10%, Sjögren syndrome (SjS) 7.3%, IgG4-related disease 6.3%, vasculitis 5.5%, polymyositis and dermatomyositis 5.5%, interstitial pneumonia 2.7%.

In patients with RA, 53% were positive for both rheumatoid factor (RF) and anti-CCP antibody (median RF 155 U/mL, anti-CCP antibody 380 U/mL). The median age of diagnosis was 68 years, and 52% were female. The average serum C-reactive protein (CRP) was 1.7 mg/dL. Patients who experienced only operation for previous cancer therapy was 44%. 39% patients developed RA symptoms with in half year. As a treatment, MTX were used in 44%, SASP in 26%, PSL alone in 11%. The response to therapy was 70% overall. One patient who used MTX developed MTX-LPD (DLBCL) after 10 months.

In PMR, all cases were seronegative. The median age of diagnosis was 71 years, and 63% were female. The average CRP was 5.4 mg/dL. 41% of patients had operation for previous cancer therapy and 32% had operation and chemotherapy. All cases started using PSL (15-40mg) and responded to treatment. They all tapered PSL.

In SSC, all cases were female and mean age was 63 year old. 33% of them had breast cancer. 82% had centromere antibody and the median titer of the antibody were 1280. Interestingly, even in SjS patients, the same antibody was positive in 38%.

In myositis, 4 out of 6 patients had ARS antibodies and their main symptom was interstitial pneumonia. No patients were positive for TIF-1y. Seeing from cancer side, 18% had colorectal cancer, 17% had breast cancer, 11% had lung cancer, 9% had gastric and uterine cancer.

Conclusion: Patients with cancer developed autoimmune diseases, and had different characteristics from primary autoimmune disease. This suggest that cancer itself and it’s therapy somehow influence to our immune systems.


AB0355
CAROTID ULTRASOUND IS MORE EFFECTIVE THAN CORONARY CALCIFICATION ASSESSMENT FOR DETECTING INDICATIONS TO STATIN THERAPY IN RHEUMATOID ARTHRITIS PATIENTS

Helen Udachkina, Diana Novikova, Tatiana Popkova, Irina Kirilova, Eugenia Markelova, Helen Gerasimova. V.A. Nasonov Research Institute of Rheumatology, Moscow, Russian Federation

Objectives: To compare the significance of the carotid ultrasound and the MDCT assessment of coronary calcification in the stratification of cardiovascular risk and the detection of indications for lipid-lowering therapy in patients with RA.

Methods: Ninety two patients with RA are included (ACR/EULAR, 2010), 74% are women, the median of age is 54 [41.5; 60] years, median of disease duration - 6 [5; 21] months, median of DAS28 (ESR) - 5.2 [5.0; 6.9], without cardiovascular diseases and diabetes mellitus, severe chronic renal failure (GFR <80 ml/min x 1.73m²). Arterial hypertension was detected in 57% of patients, dyslipidemia – in 50%, 63% of women were in postmenopause. Initially, the cardiovascular risk was assessed using the mSCORE scale, and then again, taking into account the results of carotid ultrasound and MDCT assessment of coronary calcification.

Results: After assessing the cardiovascular risk on the mSCORE scale 41.3% of patients with RA were classified as low risk (n = 38), medium risk – 38% (n = 35), high risk – 15.2% (n = 14), very high risk - 5.5%.